New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of ...

Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s Potential to Address Cancers with High Unmet Medical Need CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate ...

CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing ...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for ...

Razer notes that Snap Tap may not be as effective with just any Razer laptop or desktop keyboard. It’s best in combination ...

CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug ...

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the <a target=_blank href=https ...

Fort Worth, Texas, clinical-stage biopharmaceutical company Actuate said elraglusib has shown a favorable safety profile and antitumor activity across several solid tumors, including melanoma, Ewing ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CHICAGO and FORT WORTH, Texas, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...